Trikafta (Copackaged) is owned by Vertex Pharms Inc.
Trikafta (Copackaged) contains Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor.
Trikafta (Copackaged) has a total of 27 drug patents out of which 0 drug patents have expired.
Trikafta (Copackaged) was authorised for market use on 21 October, 2019.
Trikafta (Copackaged) is available in tablet;oral dosage forms.
Trikafta (Copackaged) can be used as treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a compound of claim 1 or composition of claim 29 of us11426407, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with an effective amount of elx, tez, and iva, treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor, treatment of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene using a solid composition comprising elexacaftor, tezacaftor, amorphous ivacaftor, and less than about 30% crystalline ivacaftor; treatment of cf in patients 12 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva; treatment of cf in patients 6 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva, treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily elx (200 mg or 100 mg); tez; and iva, treatment of cystic fibrosis in patients aged 12 years and older who have one f508del mutation and one r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor, treatment of cf in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a responsive mutation based on in vitro data by administering elexacaftor, ivacaftor, and a solid dispersion of tezacaftor and a polymer, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor, treatment of cf in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering the composition recited in us 11564916 claim 1, treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621, treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva, treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor.
Drug patent challenges can be filed against Trikafta (Copackaged) from 2023-10-22.
The generics of Trikafta (Copackaged) are possible to be released after 08 December, 2037.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(3 years from now) | |
US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(3 years from now) | |
US11426407 | VERTEX PHARMS INC | NA |
Oct, 2035
(12 years from now) | |
US10758534 | VERTEX PHARMS INC | NA |
Oct, 2035
(12 years from now) | |
US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(2 years from now) | |
US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(3 years from now) | |
US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(3 years from now) | |
US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(3 years from now) | |
US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(3 years from now) | |
US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(4 years from now) | |
US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) | |
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) | |
US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(7 years from now) | |
US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(7 years from now) | |
US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(10 years from now) | |
US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(14 years from now) | |
US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 8, 2024 |
New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 2023-10-22
Market Authorisation Date: 21 October, 2019
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatm...
Dosage: TABLET;ORAL
118
United States
39
European Union
28
Japan
23
Australia
20
China
20
Israel
18
Spain
16
Canada
16
Hungary
15
New Zealand
14
Poland
14
Slovenia
14
Denmark
14
Mexico
14
Portugal
13
Lithuania
12
Russia
11
Brazil
11
RS
11
Croatia
9
Cyprus
8
Hong Kong
7
Korea, Republic of
6
ME
6
Morocco
5
Taiwan
5
South Africa
5
Singapore
4
Chile
4
Argentina
4
EA
3
Colombia
2
Ukraine
2
Uruguay
2
Norway
1
Saudi Arabia
1
Peru
1
Luxembourg
1
Netherlands
1
India
1
Ecuador
1
Moldova, Republic of
1
Jordan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic